CXCL9 and neoplasm: The cDC1-mediated anti-tumor immunity is limited by factors such as tumor-derived granulocyte colony-stimulating factor (G-CSF), which inhibits cDC1 development through the suppression of IRF8, as well as by hepatitis A virus cellular receptor 2 HAVCR2 (better known as TIM-3), which controls the DNA uptake into, and the cGAS/STING dependent expression of T cell–recruiting chemokines (CXCL9 and CXCL11) by, intratumoral DC [50, 51].